Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial
about
Targeted therapy of gastrointestinal stromal tumoursThe GIST of targeted therapy for malignant melanomaMedical management of metastatic medullary thyroid cancerKey messages from the BFR14 trial of the French Sarcoma Group.Early outcomes of exon 11 mutants in GIST treated with standard dose Imatinib.Practical aspects of risk assessment in gastrointestinal stromal tumors.Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib.External beam radiation therapy for locally advanced and metastatic gastrointestinal stromal tumors.Lessons learned from the study of 10,000 patients with soft tissue sarcoma.The efficacy of adjuvant imatinib therapy in improving the prognosis of patients with colorectal gastrointestinal stromal tumours.Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion.Treatment and Prognoses in Patients With Primary Gastrointestinal Stromal Tumors ≥10 cm: A Single-Institution Experience in China.Laparoscopic Versus Open Resection of Small Bowel Gastrointestinal Stromal Tumors: Systematic Review and Meta-Analysis.Retrospective analysis of 85 cases of intermediate-risk gastrointestinal stromal tumor.How best to manage gastrointestinal stromal tumor.Gastrointestinal stromal tumours: from KIT to succinate dehydrogenase.Gastrointestinal stromal tumors: who should get imatinib and for how long?Managing GIST in the imatinib era: optimization of adjuvant therapy.Late hepatic metastasis from a duodenal gastrointestinal stromal tumor (29 years after surgery): report of a case and review of the literature.A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.The Role of Surgery in Metastatic Gastrointestinal Stromal Tumors.Current Standard and Future Perspectives in the Treatment of Gastrointestinal Stromal Tumors.Principles of Kinase Inhibitor Therapy for Solid Tumors.Incorporation of NLR into NIH stratification system increases predictive accuracy for surgically resected gastrointestinal stromal tumors.Is multivisceral resection in locally advanced gastrointestinal stromal tumours an acceptable strategy?Considering the role of radiation therapy for gastrointestinal stromal tumorGastric and small intestine gastrointestinal stromal tumors: Do outcomes differ?A Phase 2 Study of the Hsp90 Inhibitor AUY922 as Treatment for Patients with Refractory Gastrointestinal Stromal Tumors.Current research and treatment for gastrointestinal stromal tumors.Surgery for gastrointestinal stromal tumors (GISTs) of the stomach and small bowel: short- and long-term outcomes over three decades.Dermatofibrosarcoma protuberans and gastrointestinal stromal tumor as models for targeted therapy in soft tissue sarcomas.Role of immune microenvironment in gastrointestinal stromal tumours.Genotype and risk of tumour rupture in gastrointestinal stromal tumour.Long-term Results of Adjuvant Imatinib Treatment for Localized Gastrointestinal Stromal Tumors after SurgeryPatient-derived organoid models help define personalized management of gastrointestinal cancer.Management of hemorrhage in gastrointestinal stromal tumors: a review.Clinicopathological Features and Prognosis of Primary GISTs with Tumor Rupture in the Real World.Gastrointestinal stromal tumors: A multidisciplinary challenge.Prognostic Analysis of Duodenal Gastrointestinal Stromal Tumors.Advances and Challenges on Management of Gastrointestinal Stromal Tumors.
P2860
Q26745633-C0BD22F9-3A09-4B1D-801D-1D7CFFDE22FFQ26827092-8CB52697-CDB1-4EEF-B82E-DD2239D4DF81Q27005897-178B271E-AA2F-4F48-A5D0-CDE7ABD4EA6CQ30245384-9945A0CD-7162-4909-8B79-9E899F87337EQ33575310-1E253B95-A595-4C28-A19C-244F1FE2A7D4Q34021413-3487EBB0-499E-4538-AA04-8B5FB23D2410Q34407270-87AEFC3B-3A61-4588-A066-B1DB3BA51D5CQ34461532-4D658257-24D8-4637-88F4-EDF90483BE44Q34663883-E672F32B-DE49-41C1-826E-ADC149D6D886Q35759790-58589985-2195-42B1-84C7-177C0B2FEC55Q35820539-4538AB0E-9817-4863-A64B-1FF5853084F1Q36196622-94F32400-8A1B-46D7-9F4A-C28AC94C96A3Q36412090-E905B8D6-FB9B-4847-8717-2816BF874A66Q37705793-547E3143-5591-49B5-9AD7-88C5D20E5E73Q37743051-9D74C985-71A1-4BC4-BC17-B5A90C449D1EQ38151827-D91EC880-1227-4F2B-8642-9277A25C5751Q38257940-C1B422E8-00D3-4EDE-9057-04FE5B83EDF5Q38262193-640E8DA9-082D-4893-8301-9C6615169C19Q38365761-0D78F6A8-8398-43D0-A391-87EEFCB289C4Q38584379-C361D42E-29C2-46BF-BA3C-A4A075E71575Q38714790-23CD1114-9296-469D-98BF-6CE8FEB32448Q38734000-A017BB81-9A82-4D0F-9970-229557A20E55Q38802154-6E55505E-09C0-462C-BEED-B23A4383BBA7Q39049191-7ABD775C-C1E7-4D13-8970-D6E28C1FE643Q39735609-B664B9EC-5089-42A3-9E3B-38472800E5DFQ39754896-ACC8DA5A-5C83-4C2E-913A-BF27468EA203Q40457832-A5524E8B-6E60-4C33-A5C9-8B5894A6DF4EQ40666673-950E5BE4-342F-4487-87E7-1AC72F8F6286Q42337115-7E30D082-2E4E-44B5-B364-C4090CC92F97Q44840077-89D40F7D-87C7-4147-9878-0FA9F341A010Q47681398-206F189C-409C-4562-95C7-34AAFFD752B9Q47856440-FB083D8A-CA46-47E0-963C-38C31D075BBEQ48229455-B493D871-BA9E-4AE9-A59D-97BD48C2B527Q49648852-A2FE6743-5BDD-4389-B2EC-C93E221A5192Q50010294-DB75DF53-8DD9-49B5-8FFF-B3A40124AF61Q52562706-CE4894A0-4279-41C7-B767-E21D6285599EQ53822324-43B43E51-26D0-4F74-A812-F7ABBDEFEC4CQ54964592-24965BC1-8B07-47B4-897E-E7A7B649348DQ55038772-25FE3949-178E-4F27-8453-BD598D84E8E6Q55263134-05808E99-0FE1-4B01-B759-3682DBA5509C
P2860
Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Long-term results of adjuvant ...... ance) intergroup phase 2 trial
@ast
Long-term results of adjuvant ...... ance) intergroup phase 2 trial
@en
type
label
Long-term results of adjuvant ...... ance) intergroup phase 2 trial
@ast
Long-term results of adjuvant ...... ance) intergroup phase 2 trial
@en
prefLabel
Long-term results of adjuvant ...... ance) intergroup phase 2 trial
@ast
Long-term results of adjuvant ...... ance) intergroup phase 2 trial
@en
P2093
P2860
P50
P1433
P1476
Long-term results of adjuvant ...... ance) intergroup phase 2 trial
@en
P2093
American College of Surgeons O ...... or Clinical Trials in Oncology
Christopher Corless
Cristina R Antonescu
George D Demetri
Jeffrey Norton
Kouros Owzar
Margaret von Mehren
Martin D McCarter
Peter W T Pisters
Ronald P DeMatteo
P2860
P304
P356
10.1097/SLA.0B013E3182A15EB7
P407
P577
2013-09-01T00:00:00Z